Cite

HARVARD Citation

    Zeng, W. et al. (2022). Engineering Novel CD19/CD22 Dual-Target CAR-T Cells for Improved Anti-Tumor Activity. Cancer investigation. pp. 282-292. [Online]. 
  
Back to record